Month: December 2023

FG Trade A growing number of mutual funds are converting to exchange-traded funds, which is a positive trend for investors, experts say. Since early 2021, there have been more than 70 mutual fund to ETF conversions, including nearly three dozen in 2023, according to Morningstar Direct, and experts say more conversions are coming. “It’s steadily
0 Comments
Rows of twinkling lights and the sweet aroma of mulled wine — ’tis the season that Christmas markets come alive. But if visiting one Christmas market isn’t enough, a new cruise explores 20 markets in a single trip. Luxury river cruising company European Waterways‘ new “Christmas Markets Cruise” departs from Strasbourg, France and sails through
0 Comments
Is the Republican Foreign Pollution Fee Act a Carbon Price? Skip to content Home • Blog • Is the Foreign Pollution Fee Act a Carbon Price? A national-level carbon price—a taxA tax is a mandatory payment or charge collected by local, state, and national governments from individuals or businesses to cover the costs of general
0 Comments
In this article WBD Follow your favorite stocksCREATE FREE ACCOUNT Timothee Chalamet stars as a young Willy Wonka in Warner Bros.’ “Wonka.” Warner Bros. Discovery A younger, sweeter Willy Wonka enters theaters this weekend. Oh, and he does a lot more singing. Expectations are high that “Wonka” will deliver families to theaters, as the film
0 Comments
Valentinrussanov | E+ | Getty Images Retirement balances for midcareer workers declined between 2019 and 2022, despite gains on financial assets like stocks over that period, according to new research. However, the loss isn’t necessarily as bad as it may initially seem, financial experts said. Median combined 401(k) plans and individual retirement account balances for
0 Comments
In this article MRK MRNA Follow your favorite stocksCREATE FREE ACCOUNT An exterior view of Moderna’s clinical manufacturing facility.  David L. Ryan | Boston Globe | Getty Images Moderna and Merck‘s experimental cancer vaccine, when used in combination with Merck’s blockbuster therapy Keytruda, reduced the risk of death or relapse in patients with the most
0 Comments